As of January 1, Oregon is the first U.S. state to allow adult use of psilocybin or "magic" mushrooms, a naturally occurring psychedelic, wrote Andrew Jacobs for the NY Times. The hypothesis for mental health clinicians is that Psilocybin and other psychedelics promote neuroplasticity or "a rewiring of the brain that gives patients fresh perspectives on longstanding psychiatric problems," added the NY Times story. Publicly traded companies in the space include: Cybin (CYBN), Atai Life Sciences (ATAI), Compass Pathways (CMPS), Mind Medicine (MNMD), Seelos Therapeutics (SEEL) and Numinus Wellness (NUMIF). Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYBN: